Minerva Neurosciences, Inc. (NERV) is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on pioneering innovative therapies for central nervous system disorders. With a robust pipeline targeting significant unmet needs in neuropsychiatric diseases, the company emphasizes advancing research to improve therapeutic outcomes for patients facing complex neurological challenges. Leveraging cutting-edge scientific advancements and led by a seasoned management team, Minerva is strategically positioned to make meaningful contributions to the landscape of neuroscience and mental health care. Show more

Location: 1500 DISTRICT AVENUE, BURLINGTON, MA, UNITED STATES, 01803, Burlington, MA, 01803, USA | Website: https://www.minervaneurosciences.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

26.92M

52 Wk Range

$1.15 - $6.41

Previous Close

$4.22

Open

$4.29

Volume

78,067

Day Range

$4.13 - $4.92

Enterprise Value

188.9M

Cash

12.29M

Avg Qtr Burn

-2.916M

Insider Ownership

3.60%

Institutional Own.

19.16%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Roluperidone (5-HT2A antagonist) Details Schizophrenia	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Seltorexant (Orexin2 antagonist) Details Insomnia, Mood disorders	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.